Kings Path Partners LLC Sells 806 Shares of Cencora, Inc. (NYSE:COR)

Kings Path Partners LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR) by 11.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,545 shares of the company’s stock after selling 806 shares during the quarter. Kings Path Partners LLC’s holdings in Cencora were worth $1,471,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of COR. Arizona State Retirement System grew its stake in shares of Cencora by 6.3% in the second quarter. Arizona State Retirement System now owns 52,047 shares of the company’s stock valued at $11,726,000 after buying an additional 3,089 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Cencora by 11.5% during the 2nd quarter. Private Advisor Group LLC now owns 6,785 shares of the company’s stock worth $1,529,000 after purchasing an additional 700 shares during the last quarter. Candriam S.C.A. raised its holdings in shares of Cencora by 21.9% in the 2nd quarter. Candriam S.C.A. now owns 7,897 shares of the company’s stock valued at $1,779,000 after purchasing an additional 1,420 shares during the period. Savant Capital LLC lifted its stake in Cencora by 2.1% in the 2nd quarter. Savant Capital LLC now owns 6,511 shares of the company’s stock valued at $1,467,000 after purchasing an additional 132 shares during the last quarter. Finally, SRS Capital Advisors Inc. grew its holdings in Cencora by 6.7% during the second quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company’s stock worth $752,000 after purchasing an additional 210 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on COR. Barclays raised their price objective on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Wells Fargo & Company dropped their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Evercore ISI lifted their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, UBS Group increased their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is currently owned by corporate insiders.

Cencora Price Performance

COR traded up $0.15 on Monday, hitting $229.35. 361,763 shares of the stock were exchanged, compared to its average volume of 930,216. The firm has a market capitalization of $44.33 billion, a price-to-earnings ratio of 30.54, a PEG ratio of 1.54 and a beta of 0.45. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a 12 month low of $208.58 and a 12 month high of $253.27. The business has a 50-day moving average of $237.44 and a two-hundred day moving average of $233.60.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.96%. Cencora’s dividend payout ratio is presently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.